Bellevue Group AG Has $68.18 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Bellevue Group AG decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 19.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,017,038 shares of the medical device company’s stock after selling 251,649 shares during the quarter. DexCom makes up about 1.1% of Bellevue Group AG’s investment portfolio, making the stock its 26th biggest holding. Bellevue Group AG’s holdings in DexCom were worth $68,182,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Caisse DE Depot ET Placement DU Quebec raised its holdings in DexCom by 235.0% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 135,323 shares of the medical device company’s stock worth $9,072,000 after acquiring an additional 94,923 shares in the last quarter. PDT Partners LLC increased its position in shares of DexCom by 164.3% during the 3rd quarter. PDT Partners LLC now owns 52,290 shares of the medical device company’s stock worth $3,506,000 after purchasing an additional 32,508 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of DexCom by 4.6% during the 3rd quarter. Captrust Financial Advisors now owns 23,051 shares of the medical device company’s stock worth $1,545,000 after purchasing an additional 1,022 shares in the last quarter. Suvretta Capital Management LLC boosted its holdings in shares of DexCom by 438.8% in the 3rd quarter. Suvretta Capital Management LLC now owns 31,680 shares of the medical device company’s stock valued at $2,124,000 after buying an additional 25,800 shares during the last quarter. Finally, Public Sector Pension Investment Board grew its stake in shares of DexCom by 5.9% in the third quarter. Public Sector Pension Investment Board now owns 17,842 shares of the medical device company’s stock valued at $1,196,000 after buying an additional 1,000 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Royal Bank of Canada dropped their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company upped their target price on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. JPMorgan Chase & Co. lifted their price target on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Leerink Partners lowered their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $104.59.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,431 shares of company stock worth $399,319 in the last quarter. 0.30% of the stock is currently owned by corporate insiders.

DexCom Trading Down 0.1 %

Shares of DexCom stock opened at $77.99 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The firm has a 50-day moving average of $71.39 and a 200-day moving average of $87.85. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The stock has a market cap of $30.46 billion, a PE ratio of 46.70, a PEG ratio of 2.38 and a beta of 1.17.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.